Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002


Delayed Japan Exchange  -  01:00 2022-12-09 am EST
9543.00 JPY   -0.89%
12/05Retail Sector Strength Edges Japan Shares Into Green
12/01Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
11/30Japan's Nikkei rises as Powell comments lift Wall Street
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eisai says Alzheimer's drug succeeds in slowing cognitive decline

09/27/2022 | 07:37pm EST
FILE PHOTO: The logo of Eisai Co Ltd is displayed at the company headquarters in Tokyo

(Reuters) - An experimental Alzheimer's drug developed by Eisai Co Ltd and Biogen Inc significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, the companies said on Tuesday.

The injected drug, lecanemab, slowed progress of the brain-wasting disease by 27% compared to a placebo, meeting the study's main goal, and offering an apparent win for the companies and potentially for patients and their families desperate for an effective treatment.

Eisai said the results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer's can delay advance of the debilitating disease.

Analysts, such as Salim Syed at Mizuho Securities, have said the results would be considered a "win" if lecanemab slowed the rate of decline by around 25%, and that shares of both companies could jump on the news.

Lecanemab, like the companies' previous drug Aduhelm, is an antibody designed to remove those amyloid deposits. Unlike Aduhelm, lecanemab targets forms of amyloid that have not yet clumped together.

The so-called amyloid hypothesis has been challenged by some scientists, particularly after the U.S. Food and Drug Administration's controversial approval of Aduhelm in 2021 based on its plaque-clearing ability rather than proof that it helped slow cognitive decline. The decision came after the FDA's own panel of outside experts had advised against approval.

Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry.

Eisai, leader of the 50-50 partnership's lecanemab program, is seeking FDA approval under the same accelerated pathway as Aduhelm, with a decision expected in early January. But on Tuesday the Japanese drugmaker said it will use the new efficacy results to submit lecanemab for traditional FDA review.

The company said it will also seek authorization in Japan and Europe during its current fiscal year, ending March 31.

The Phase III trial evaluated the drug's ability to reduce cognitive and functional decline based on the Clinical Dementia Rating-Sum of Boxes (CDR-SB), a numerical scale used to quantify the severity of dementia in patients in areas such as memory, orientation, judgment and problem solving and personal care.


The rate of ARIA-E, a brain swelling side effect associated with anti-amyloid treatments, was 12.5% in the lecanemab group, versus 1.7% in the placebo group.

While the side effect showed up on imaging, many of these cases were not symptomatic, the companies said. Symptomatic brain swelling was seen in 2.8% of those in the lecanemab group and none of the placebo group, they said.

The trial also tracked the rate of micro hemorrhages in the brain, which occurred at a rate of 17% in the lecanemab group, and 8.7% in the placebo group.

The total incidence of both conditions was 21.3% in the lecanemab group and 9.3% in the placebo group, rates that fell within an expected range, the companies said.

Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost.

The controversy and reluctance by some payers to cover Aduhelm led Biogen to slash the drug's price to $28,000 per year from an initial $56,000.

But Medicare, the U.S. government health plan for people 65 and older, this year said it would only pay for Aduhelm if patients were enrolled in a valid clinical trial, which sharply curtailed the medication's use. Since Alzheimer's is a disease of aging, an estimated 85% of patients eligible for the drug are covered by the government plan.

The number of Americans living with Alzheimer's is expected to rise to around 13 million by 2050 from more than 6 million currently, according to the Alzheimer's Association. Globally, that figure could rise to 139 million by 2050 without an effective treatment, according to Alzheimer's Disease International.

Other plaque-targeting antibodies in late-stage development for Alzheimer's patients include Roche Holding AG's gantenerumab and Eli Lilly and Co's donanemab.

(Reporting by Deena Beasley in Los Angeles and Julie Steenhuysen in Chicago; Editing by Bill Berkrot)

By Deena Beasley and Julie Steenhuysen

ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. -1.29% 285.37 Delayed Quote.20.50%
EISAI CO., LTD. -0.89% 9543 Delayed Quote.46.12%
ELI LILLY AND COMPANY -2.90% 360.99 Delayed Quote.34.60%
ROCHE HOLDING AG 0.54% 304.6 Delayed Quote.-19.65%
All news about EISAI CO., LTD.
12/05Retail Sector Strength Edges Japan Shares Into Green
12/01Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio ..
11/30Japan's Nikkei rises as Powell comments lift Wall Street
11/30Roche shutters most trials of Alzheimer's drug after failed trials
11/30Eisai, Biogen Alzheimer's drug could be available to some next year
11/30Trending: Eisai/Biogen Alzheimer's Drug Shows Positive Results
11/30MarketScreener's World Press Review : November 30, 2..
11/30Eisai - eleven experts from leading medical institutions and eight experts from eisai p..
11/30Eisai presents full results of lecanemab phase 3 confirmatory clarity ad study for earl..
11/30Futures rise as focus turns to Powell speech
More news
Sales 2023 744 B 5 459 M 5 459 M
Net income 2023 56 864 M 417 M 417 M
Net cash 2023 203 B 1 491 M 1 491 M
P/E ratio 2023 48,3x
Yield 2023 1,70%
Capitalization 2 738 B 20 077 M 20 077 M
EV / Sales 2023 3,40x
EV / Sales 2024 3,16x
Nbr of Employees 11 322
Free-Float 93,3%
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 13
Last Close Price 9 543,00 JPY
Average target price 9 000,00 JPY
Spread / Average Target -5,69%
EPS Revisions
Managers and Directors
Haruo Naito Manager-Research & Development Promotions
Tatsuyuki Yasuno Manager-Corporate Planning
Yasuhiko Katoh Chairman
Keisuke Naito Executive Officer & Head-Global IT Headquarters
Yasushi Okada Manager-Business Planning
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.46.12%20 077
JOHNSON & JOHNSON3.58%459 469
NOVO NORDISK A/S25.40%295 189
PFIZER, INC.-12.31%290 321
ABBVIE INC.20.43%288 271